CINECA IRIS Institutional Research Information System

BERTANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.949
EU - Europa 1.029
AS - Asia 364
AF - Africa 89
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
Totale 3.451
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.919
IT - Italia 377
SE - Svezia 214
SG - Singapore 153
BG - Bulgaria 118
AT - Austria 88
CN - Cina 82
GB - Regno Unito 70
DE - Germania 68
CI - Costa d'Avorio 45
VN - Vietnam 40
CA - Canada 27
IN - India 26
FR - Francia 25
HK - Hong Kong 22
NG - Nigeria 22
SN - Senegal 22
NL - Olanda 18
FI - Finlandia 16
AU - Australia 13
PL - Polonia 12
TR - Turchia 9
JP - Giappone 6
BE - Belgio 4
CH - Svizzera 4
ES - Italia 4
ID - Indonesia 4
IR - Iran 4
KR - Corea 4
MY - Malesia 4
EU - Europa 3
MX - Messico 3
TW - Taiwan 3
UA - Ucraina 3
BR - Brasile 2
PK - Pakistan 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EC - Ecuador 1
GR - Grecia 1
IL - Israele 1
KZ - Kazakistan 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 3.451
Salva come PNG Salva come JPEG
Città #
Fairfield 236
Chandler 213
Woodbridge 152
Ashburn 133
Ann Arbor 127
Sofia 118
Houston 111
Seattle 90
Wilmington 86
Cambridge 85
New York 77
Serra 74
Vienna 70
Princeton 64
Florence 57
Lawrence 55
London 47
Milan 46
Abidjan 45
Medford 44
Singapore 38
Pisa 31
Beijing 27
Dakar 22
Hong Kong 22
Lagos 22
Ottawa 21
Bremen 20
Frankfurt am Main 15
Redmond 15
Dearborn 14
Los Angeles 14
San Diego 14
Dong Ket 13
Des Moines 12
Ogden 11
Nanjing 9
Redwood City 9
Boulder 8
Groningen 8
Izmir 8
Norwalk 8
Rome 8
Kent 7
Hebei 6
Kunming 6
Amsterdam 5
Grosseto 5
Nanchang 5
Washington 5
Boardman 4
Brussels 4
Cascina 4
Changsha 4
Deiva Marina 4
Hefei 4
Jacksonville 4
Lappeenranta 4
Lucca 4
Phoenix 4
Shenyang 4
Toronto 4
Bern 3
Bethesda 3
Castelnovo di Sotto 3
Cepagatti 3
Chicago 3
Edgware 3
Esslingen am Neckar 3
Fondi 3
Jamshedpur 3
Marseille 3
Munich 3
Palermo 3
Pietrasanta 3
Warsaw 3
Bologna 2
Carrara 2
Catania 2
Charlotte 2
Dallas 2
Duncan 2
Guangzhou 2
Hamburg 2
Helsinki 2
Jakarta 2
Karachi 2
Lancaster 2
Livorno 2
Llanelli 2
Madrid 2
Mardi 2
Mariano Comense 2
Melbourne 2
Mumbai 2
Nagoya 2
Naples 2
San Giovanni Valdarno 2
Semarang 2
Shenzhen 2
Totale 2.476
Salva come PNG Salva come JPEG
Nome #
Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease 151
Lactobacillus Casei DG® in Patients with Irritable Bowel Syndrome: Not Only a Change of the Gut Microbiota. A Pilot Study 145
Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? 126
Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: A comparative study 115
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 114
Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring 108
Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique 106
Esophageal testing: What we have so far 105
Barrett's esophagus in 2016: From pathophysiology to treatment 105
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 105
Irritable bowel syndrome and chronic constipation: Fact and fiction 102
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 102
Are PPI responder patients always confirmed as GERD patients? A MII-PH study. 91
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 87
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 84
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD 81
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 81
Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn 79
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 77
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 76
Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis 74
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 67
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 66
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 63
The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment 61
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 57
From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting 56
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 56
A low-FODMAP diet for irritable bowel syndrome: Some answers to the doubts from a long-term follow-up 55
Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study 53
Low fermentable oligo-di-and mono-saccharides and polyols (Fodmaps) or gluten free diet: What is best for irritable bowel syndrome? 52
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 50
Fecal calprotectin: Current and future perspectives for inflammatory bowel disease treatment 49
Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults 49
Oral sucrosomial iron is as effective as intravenous ferric carboxy‐maltose in treating anemia in patients with ulcerative colitis 45
Esophageal bolus contact time and chemical clearance may differentiate patients with non-erosive reflux disease: an impedance-pH monitoring study 42
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry 38
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply 37
HOSPITALIZATION FOR DRUG INFUSION DOES NOT INCREASE COVID INFECTION RATE, IBD RELAPSES DUE TO INFECTIONS AND LEVELS OF ANXIETY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY 36
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply 33
Ig Glycosylation in Ulcerative Colitis: It’s Time for New Biomarkers 33
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 31
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 31
Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak 30
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 29
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 28
Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: An observational multicentre study 25
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 25
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? 25
Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases 24
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 23
Vitamin d-related genetics as predictive biomarker of clinical remission in adalimumab-treated patients affected by crohn’s disease: A pilot study 22
Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF 20
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 20
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? 19
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 19
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 18
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 17
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 12
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients 11
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue 9
Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy 8
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 7
P965 Ulcerative proctitis treated with biologics: is it too hard to treat? 6
Ulcerative proctitis treated with biologics: is it too hard to treat? 5
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 4
Totale 3.580
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.664
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.664
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020449 0 49 71 33 40 44 41 37 57 27 46 4
2020/2021463 20 11 24 128 45 10 37 19 50 20 49 50
2021/2022605 6 21 25 29 105 81 36 29 40 33 54 146
2022/2023947 112 159 89 57 96 104 17 62 173 2 76 0
2023/2024613 39 42 103 34 73 95 55 27 8 19 42 76
2024/20259 9 0 0 0 0 0 0 0 0 0 0 0
Totale 3.580